Podcast appearances and mentions of Steve Rosenberg

Kate Adie presents stories from Alaska, Washington, South Korea, Chile and France.From the military fly-past to the grandiose entrance on the red carpet, to the press conference, without any questions, the meeting between Donald Trump and Vladimir Putin drew dismay from Western governments. Steve Rosenberg was in Alaska - and reflects on the aftermath.After the pomp and pageantry of Donald Trump's meeting with Vladimir Putin, six European leaders rushed to Washington DC this week to meet with the US President in a show of solidarity with Volodymyr Zelensky. Tom Bateman followed the twists and turns and reflects on what was actually achieved at the White House.Vladimir Putin has come to rely on support from North Korea to bolster his troops in Ukraine. Pyongyang is now sending thousands of construction workers, to help fill a huge labour shortage created by the war. Jean Mackenzie has spoken to six workers who've managed to escape.In the hills of southern Chile and is an alluring tourist destination - a German-style village - but it was once home to a religious sect run by a manipulative and abusive leader. The Chilean government wants to expropriate some of its land to create a memorial for the people who were tortured and killed there during Pinochet's regime. But Grace Livingstone finds, it's proving divisive.In the Loire valley the summer months bring both extended bank holiday weekends in France and the return in the last few decades of the 'Guinguettes', waterside outdoor bars and dance halls which were once popular in the 17th and 18th centuries. Jamie Smith-Maillet went to soak up the atmosphereSeries Producer: Serena Tarling Production Coordinators: Katie Morrison & Sophie Hill Editor: Richard Vadon

After headline-grabbing meetings in Alaska and Washington, members of the world's media are on high alert, as Donald Trump talks up the chances of a summit between Volodymyr Zelensky and Vladimir Putin. So, has a change in tone from the US on security guarantees moved the needle? Is a temporary ceasefire now less likely? And crucially, would a face-to-face encounter with a leader he's long sought to delegitimise, mark a clear concession from President Putin?This week, the Ukrainecast studio is hosting an unprecedented meeting of its own, as the BBC's Russia editor Steve Rosenberg, and Ukraine correspondent James Waterhouse unite in person for the first time. They join Jamie to answer all of your questions, and consider where we stand following this latest diplomatic frenzy.Today's episode is presented by Jamie Coomarasamy. The producers were Laurie Kalus and Polly Hope. The technical producer was James Piper. The series producer is Tim Walklate. The senior news editor is Sam Bonham.You can fill out our audience questionnaire here: bit.ly/ukrainecastfeedback Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

On this episode of Old Newscast, we look at how an unknown bureaucrat with a mysterious past unexpectedly rose to president of Russia.Adam is joined by the BBC's Russia editor, Steve Rosenberg, and Russia reporter for The Washington Post and author, Catherine Belton.They discuss how chaos in Russia in the 1990s allowed Putin's rise to power, Boris Yeltsin's surprise resignation and why Putin refused to campaign.You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers.You can join our Newscast online community here: https://discord.gg/m3YPUGv9New episodes released every day. If you're in the UK, for more News and Current Affairs podcasts from the BBC, listen on BBC Sounds: https://bit.ly/3ENLcS1Newscast brings you daily analysis of the latest political news stories from the BBC.It was presented by Adam Fleming. It was made by Joe Wilkinson with Miranda Slade, and Kris Jalowiecki. The technical producer was Ben Andrews. The assistant editor is Chris Gray. The editor is Sam Bonham.

It has been a bruising week domestically for President Zelensky, as a controversial move to overhaul key anti-corruption bodies saw thousands of Ukrainians take to the streets in the biggest nationwide demonstrations held since Russia's full-scale invasion. With the EU already raising concerns, could this undermine his recent progress on the diplomatic stage, particularly when it comes to the Trump administration?To discuss the fallout, Lucy is joined by chief international correspondent Lyse Doucet and Russia editor Steve Rosenberg, who also react to reports of a potential meeting between Donald Trump and Vladimir Putin in China. Plus - after representatives from Russia and Ukraine met in Istanbul for the shortest round of peace talks yet - we get Vitaly's take from Turkey. Today's episode is presented by Lucy Hockings. The producers were Laurie Kalus, Julia Webster and Polly Hope. The technical producer was Hannah Montgomery. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

This week, Alan and Lionel discuss every editor's nightmare: what do you do if news breaks just as the papers have gone to print?They also explain “pyjama injunctions”, and are asked about whether the BBC's Russia editor, Steve Rosenberg, is still safe while reporting from Moscow.Plus, Lionel responds to a listener asking about his Substack. Hosted on Acast. See acast.com/privacy for more information.

Kate Adie introduces dispatches from the Turkey-Iran border, Russia, the USA, Paraguay and Transylvania.Israel's attacks on Iran led thousands of people to flee cities under fire - now they must decide whether to return home, fearing further strikes and a regime still in power. Orla Guerin has been on the Turkey-Iran border, where she spoke to Iranians escaping the war, and others going back home to their families still in the country.As Western leaders gathered for the G7 and NATO summits, President Putin held his own annual international gathering: the St Petersburg International Economic Forum. While an economic summit in name, Steve Rosenberg found the focus this year to be much more geared towards the promotion of Russia's military might.Donald Trump's sudden decision to attack Iran's nuclear sites was met with concern by many in Washington – including some of his most ardent supporters. But the dissenters were quick to fall back in line, says Bernd Debusmann Jr in Washington DC.The herbal drink Mate is hugely popular in Argentina - football legend Lionel Messi is a big fan. But across the border in Paraguay, Jane Chambers finds Mate enthusiasts are miffed that their bigger neighbour is seen as the originator of Mate, claiming Paraguay is the true home of Mate culture.And finally, in Transylvania, Sara Wheeler explores the ebb and flow of a centuries-old Saxon settlement nestled amid ancient forests.Series Producer: Serena Tarling Production Coordinators: Sophie Hill & Gemma Ashman Editor: Richard Fenton-Smith

Sarah Moss, the celebrated author of Ghost Wall, discusses her new novel Ripeness, which oscillates between tension-filled contemporary Ireland and a heady summer in 1960s Italy. Dylan Jones discusses his new book 1975: The Year The World Forgot and debates whether this was the best year for music with chief music critic of the Daily Telegraph, Neil McCormick. After reports of an emerging deal between the UK and Greece around the status of the Elgin Marbles, we talk to Geoffrey Robertson KC, campaigner for their return, about the legal ramifications. A new statue of Stalin has appeared on the Moscow Underground at Taganskaya station. After de-Stalinisation in the 60s it seems that the Russian authorities are now reintroducing images of the former leader, showing him in a positive light and ignoring his reign of terror. Tom speaks with the BBC's man in the Russian capital, Steve Rosenberg, about what this might mean. And we finish the programme with a specially written poem from Fred D'Aguiar, Professor of English at the University of California, about the government response to the migrant deportation protests.Presenter: Tom Sutcliffe Producer: Simon Richardson

Hosted by Jane Pauley. In our cover story, Elaine Quijano reports on how an Army wife helped change military culture regarding the notification of next of kin about casualties. Also: Robert Costa sits down with Pulitzer Prize-winning novelist Anne Tyler; Kris Van Cleave explores the centenary of Delta Air Lines; Elizabeth Palmer interviews Steve Rosenberg, the BBC's "Man in Moscow"; Tracy Smith talks with music producer David Foster, the composer behind the new Broadway musical “Boop!”; and “Sunday Morning” offers previews of the summer's most anticipated movies, music, books and museum exhibits. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

After a two-hour phone call on Monday, Donald Trump and Vladimir Putin came to very different conclusions about what was agreed. The US said ceasefire negotiations between Moscow and Kyiv would start “immediately.” The Kremlin meanwhile, said there were no deadlines to move towards peace. On this episode the BBC's Russia editor Steve Rosenberg tells us about the reaction to the call in the Russian press. And - as Europe prepares to level further sanctions - Robert Fox, defence editor at the Evening Standard, tells us the West needs to prepare for a longer term conflict.Today's episode is presented by Victoria Derbyshire and Vitaly Shevchenko. The producers were Laurie Kalus and Ben Carter. The technical producers were Ben Andrews and Mike Regaard. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Today, we look at talks between world leaders and their officials in Turkey, where a breakthrough on peace in Ukraine was hoped for.Ukrainian President Volodymyr Zelensky met with Turkish leader Recep Tayyip Erdoğan in the country's capital Ankara, but Russian President Vladimir Putin stayed away despite having proposed talks.Russia editor Steve Rosenberg joins to discuss what Putin's thinking is, as does former MI6 officer Christopher Steele.And - positive news for the UK's economy. It's grew more than expected at the start of the year. Deputy economics editor Dharshini David tells Adam whether it's expected to continue to grow.You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers. You can join our Newscast online community here: https://discord.gg/m3YPUGv9New episodes released every day. If you're in the UK, for more News and Current Affairs podcasts from the BBC, listen on BBC Sounds: https://bit.ly/3ENLcS1 Newscast brings you daily analysis of the latest political news stories from the BBC. It was presented by Adam Fleming. It was made by Chris Flynn with Shiler Mahmoudi, Julia Webster, and Rufus Gray. The technical producer was James Piper. The assistant editor is Chris Gray. The editor is Sam Bonham.

In this exciting episode, Shawn sits down with Joni Wolfswinkel, alongside industry leaders Josh Huite and Steve Rosenberg, to announce a game-changing event for entrepreneurs in Houston: the Strategic Growth Accelerator! Mark your calendars for August 22, 2025, because this one-day power-packed event at Hochzeit Hall in Old Town Spring is designed to equip you with the tools, strategies, and mindset needed to elevate your business to new heights. Join us as Joni shares her expert insights on building and managing an international workforce—discover how hiring global talent can reduce costs while fueling innovation and growth. Meanwhile, Shawn, Josh, and Steve delve into what makes this event so unique: from scaling your business with proven strategies to becoming the leader your team needs. Steve Rozenberg offers his secrets to smart, effective scaling, while Josh Huite reveals how to unlock your leadership potential and inspire your team to succeed. With a wealth of experience combined, Joni, Josh, and Steve are set to share their invaluable wisdom, strategies, and practical tips that can help entrepreneurs elevate their businesses to the next level. Listeners will discover why this event is a must-attend, featuring engaging discussions that cover everything from innovative business strategies to personal growth and resilience in the competitive entrepreneurial landscape. Each speaker brings their unique perspective and expertise, providing attendees with actionable takeaways they can implement right away. This episode is a must-listen for entrepreneurs eager to accelerate their growth and gain actionable wisdom from industry veterans. Whether you're just starting out or looking to break through to the next level, the Strategic Growth Accelerator promises practical insights that can transform your business trajectory. Don't miss out on this exclusive opportunity! Early bird registration is just $297 if you sign up by May 31st—space is limited, so reserve your spot today. The Strategic Growth Accelerator Event Website Link: https://www.wolfdenevents.com/ The Strategic Growth Accelerator Event Invitation Link: https://www.eventbrite.com/e/strategic-growth-accelerator-tickets-1303026911569?aff=oddtdtcreator The Strategic Growth Accelerator Event Sponsorship Link: https://www.eventbrite.com/e/1304634088679?aff=oddtdtcreator The Strategic Growth Accelerator Happy Hour Link: https://www.eventbrite.com/e/1304625412729?aff=oddtdtcreator

After Vladimir Putin's limited ‘Easter truce' ended, we're joined by the BBC's Russia editor, Steve Rosenberg, to discuss whether the Kremlin is serious about bilateral negotiations with Ukraine. And we talk to Alexander Vindman - the former US National Security Council official, who was a star witness in Donald Trump's first impeachment inquiry. He has a lot to say about US policy on Ukraine and what the future could look like if Washington pulls out of peace talks. Today's episode is presented by Victoria Derbyshire and Vitaly Shevchenko. The producers were Laurie Kalus and Ben Carter. The technical producer was Jonny Hall. The editor is Max Deveson. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on our Discord server here: tinyurl.com/ukrainecastdiscord

Join Ericka Redic and Steve Rosenberg as they welcome Director of Education and Community Engagement at the Jewish Institute for Liberal Values (JILV), Dr. Brandy Shufutinsky. Together, they discuss how wokeism and antisemitism have infiltrated America's education system and what we can do to fight back. Brash, irreverent, and mostly peaceful! Stay in contact with […]

Steve Rosenberg, Russia Editor for BBC News, is in Moscow on the third anniversary of Russia's full-scale invasion of Ukraine.

What have Russians won and lost during the conflict in Ukraine? Three years after the start of its full-scale invasion, Russia has entered talks with Donald Trump – and not Kyiv – about ending the war. For Vladimir Putin, this could be a chance to end the conflict on his terms, and forge a new international order with Russia and the US at its centre. But what about the people who live under Putin's rule? What do Russians stand to gain from these talks? On this episode, presenter Lucy Hockings is joined by the BBC's Russia editor Steve Rosenberg.The Global Story brings you trusted insights from BBC journalists worldwide. We want your ideas, stories and experiences to help us understand and tell #TheGlobalStory. Email us at theglobalstory@bbc.com You can also message us or leave a voice note via Whatsapp on +44 330 123 9480.Producers: Peter Goffin and Mhairi MacKenzieSound engineer: Mike RegaardAssistant editor: Sergi Forcada FreixasSenior news editor: China Collins

Today, we look at President Donald Trump's claim that there's a “good possibility” that the Ukraine war could be about to end.He spoke to Russian President Putin and Ukrainian President Volodymyr Zelensky during separate phone calls. Chief international correspondent Lyse Doucet and Russia editor Steve Rosenberg talk through what we know.Chris is on to talk about stories regarding the Chancellor Rachel Reeves's CV, and her expenses when she was working for a bank in a previous job.And, the CEO of BBC News Deborah Turness is warning about the “threat” AI poses to people using it to access news.You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers.You can join our Newscast online community here: https://tinyurl.com/newscastcommunityhereNewscast brings you daily analysis of the latest political news stories from the BBC. It was presented by Adam Fleming. It was made by Chris Flynn with Shiler Mahmoudi. The technical producer was Ben Andrews. The assistant editor is Chris Gray. The editor is Sam Bonham.

In this episode, Dr. Alexandria Wise speaks with Steve Rosenberg, CEO of uMotif, recorded from the CNS Summit 2024 exhibit floor. With over four decades of experience in software development and two decades in clinical research, Steve shares his journey from early tech innovations to his current mission of revolutionizing patient engagement and site support in clinical trials.Steve discusses the pivotal role of patient-centric tools in modernizing clinical research, emphasizing the need to recognize and support patients as key contributors to advancements in medicine. He also delves into the growing challenges faced by clinical sites, the potential of AI and computer modeling to streamline trials, and his vision for a future where the industry prioritizes patient and site experiences over protocol complexity.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

After listener Margaret got in touch asking about Steve Rosenberg's life in Moscow as the BBC's Russia Editor, Nick and Amol sat down with him to find out how the country has changed over the years that he has lived there and what it's like reporting from Russia now.They talk about the challenges he faces, how he reports impartially and accurately on Vladimir Putin, how he relaxes and what it was like playing the piano for Mikhail Gorbachev.To get Amol and Nick's take on the biggest stories and insights from behind the scenes at the UK's most influential radio news programme make sure you hit subscribe on BBC Sounds. That way you'll get an alert every time we release a new episode, and you won't miss our extra bonus episodes either. GET IN TOUCH: * Send us a message or a voice note via WhatsApp to +44 330 123 4346 * Email today@bbc.co.uk The Today Podcast is hosted by Amol Rajan and Nick Robinson who are both presenters of BBC Radio 4's Today programme. Amol was the BBC's media editor for six years and is the former editor of the Independent, he's also the current presenter of University Challenge. Nick has presented the Today programme since 2015, he was the BBC's political editor for ten years before that and also previously worked as ITV's political editor. This episode was made by Lewis Vickers with Nadia Gyane and Grace Reeve. Digital production was by Nadia Gyane. The technical producer was Jonny Baker. The editor is Louisa Lewis. The executive producer is Owenna Griffiths.

Morse code transcription: vvv vvv Stephen Fry treats his chronic pain as a friend The uplifting science stories that turned heads in 2024 Hawaii volcano Warning after toddler nearly runs off cliff Blackburn Third murder arrest after Christmas Day pub row death Three migrants die attempting English Channel crossing On the fifth day of Christmas Norfolks five gold rings Who died in 2024 Notable deaths of the year Putin reaches 25 years in charge of Russia, but has he taken care of country, asks Steve Rosenberg Thousands protest in Georgia ahead of political showdown Manchester Airport train services hit by 100k cable theft

Morse code transcription: vvv vvv Who died in 2024 Notable deaths of the year Blackburn Third murder arrest after Christmas Day pub row death The uplifting science stories that turned heads in 2024 Thousands protest in Georgia ahead of political showdown Putin reaches 25 years in charge of Russia, but has he taken care of country, asks Steve Rosenberg Stephen Fry treats his chronic pain as a friend Manchester Airport train services hit by 100k cable theft Hawaii volcano Warning after toddler nearly runs off cliff Three migrants die attempting English Channel crossing On the fifth day of Christmas Norfolks five gold rings

Morse code transcription: vvv vvv Three migrants die attempting English Channel crossing Putin reaches 25 years in charge of Russia, but has he taken care of country, asks Steve Rosenberg Manchester Airport train services hit by 100k cable theft Thousands protest in Georgia ahead of political showdown Stephen Fry treats his chronic pain as a friend Hawaii volcano Warning after toddler nearly runs off cliff The uplifting science stories that turned heads in 2024 Blackburn Third murder arrest after Christmas Day pub row death Who died in 2024 Notable deaths of the year On the fifth day of Christmas Norfolks five gold rings

Morse code transcription: vvv vvv The uplifting science stories that turned heads in 2024 Who died in 2024 Notable deaths of the year Putin reaches 25 years in charge of Russia, but has he taken care of country, asks Steve Rosenberg Blackburn Third murder arrest after Christmas Day pub row death Hawaii volcano Warning after toddler nearly runs off cliff On the fifth day of Christmas Norfolks five gold rings Manchester Airport train services hit by 100k cable theft Stephen Fry treats his chronic pain as a friend Thousands protest in Georgia ahead of political showdown Three migrants die attempting English Channel crossing

Kate Adie presents stories from Russia, Mayotte, Liechtenstein and France.BBC Russia editor Steve Rosenberg is regarded as a 'propagandist' by some Russians, but a song he wrote about a Russian friend seemed to thaw the ice, and unexpectedly struck a chord with fellow Muscovites.France held a day of national mourning this week in tribute to those who died after Cyclone Chido devasted the Indian Ocean territory of Mayotte earlier this month, bringing winds of up to 160 miles per hour. Mayotte was already France's most impoverished territory, but the storm, which was the worst to hit the archipelago in 90 years, flattened areas where many people live in shacks, leaving behind fields of dirt and debris. Mayeni Jones describes the challenges of trying to reach the island when she was deployed there.Liechtenstein lays claim to being one of the worst football teams in the world. It was recently on a 40-game losing streak, until it recently faced Hong Kong on its home turf. Jacob Panons - a loyal supporter of the Hong Kong team - witnessed the stand-off between the two minnows.Thanks to his Christmas stories, Charles Dickens is often associated with this time of year. But our Paris correspondent, Hugh Schofield, has come to discover more about another passion in the Victorian novelist's life – his love of France.Series Producer: Serena Tarling Production Coordinators: Katie Morrison & Sophie Hill Editor: Richard Fenton-Smith

Today, we look at what the end of Bashar al-Assad's regime means for Syria. As huge crowds gather at a notorious Damascus prison looking for prisoners held under the Assad regime Adam speaks to Lina Sinjab, the BBC's Middle East Correspondent. He is also joined by chief Jihadist media specialist for BBC monitoring, Mina Al-Lami, who profiles the rebel group's leader and legacy. And, the Kremlin say Bashar Al-Assad has been given asylum in Moscow after fleeing from Syria. Adam speaks to Russia editor Steve Rosenberg about how the fall of the Russian-supported regime is a blow to the country's prestige. You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers. You can join our Newscast online community here: https://tinyurl.com/newscastcommunityhere Newscast brings you daily analysis of the latest political news stories from the BBC. It was presented by Adam Fleming. It was made by Jack Maclaren with Anna Harris and Maddie Drury. The technical producer was Philip Bull. The assistant editor is Chris Gray. The editor is Sam Bonham.

Donald Trump has won the US election and will make a historic return to the White House. He's said he'd end the war in 24 hours but…..can he? We hear from Ukraine correspondent James Waterhouse in Kyiv, Russia editor Steve Rosenberg in Sochi and Victoria in Washington DC. They discuss what Trump's re-election actually mean for Ukraine.Today's episode is presented by Lucy Hockings and Vitaly Shevchenko. The producers were Arsenii Sokolov and Ben Carter. The technical producer was Hannah Montgomery. The series producer is Tim Walklate. The senior news editor is Sarah Wadeson. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Israel claims a bunker under a Beirut hospital holds hundreds of millions of dollars belonging to Hezbollah. The hospital has been evacuated Brazil,Russia,India,China and South Africa, also know as BRICS, are set to have a summit meeting this week. The BBC's Steve Rosenberg tells us more And the worlds largest entertainment company Disney, has announced its CEO's successor will be announced in 2026

Russia has revealed it will boost its defence spending by a quarter to $145 billion in 2025. But is Putin's war economy sustainable? What does all this mean for life in the country? And how could it impact the war?The BBC's Steve Rosenberg joins us from a Moscow supermarket, Russian citizen ‘Gleb' explains why there are dozens of types of cola in shops, and Bloomberg's Stephanie Baker joins Carnegie's Alexander Gabuev to discuss whether Russians are feeling the pinch.Today's episode is presented by Victoria Derbyshire and Vitaly Shevchenko. The producers were Arsenii Sokolov, Cordelia Hemming and Ivana Davidovic. The technical producer was Ben Andrews. The series producer is Tim Walklate. The senior news editor is Sarah Wadeson. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Ever since the Kremlin's full-scale invasion of Ukraine there have been widespread reports of Russians reporting fellow citizens to the police for anti-war views; often leading to prosecution and, in some cases, prison sentences. It's revived memories of the Soviet past when informing on colleagues and neighbours was actively encouraged. Katya Adler speaks to our Russia editor Steve Rosenberg about the people he has met who have been caught up in this new wave of denunciations.The Global Story brings you trusted insights from BBC journalists worldwide. We want your ideas, stories and experiences to help us understand and tell #TheGlobalStory. Email us at theglobalstory@bbc.com You can also message us or leave a voice note via WhatsApp on +44 330 123 9480.Producers: Alice Aylett Roberts, Eleanor Sly and Beth Timmins.Sound Engineers: Antonio Fernandes and Rohan Madison.Assistant Editor: Sergi Forcada Freixas.Senior News Editor: Richard Fenton-Smith.

Pavel Durov, the CEO of messaging app Telegram, has been arrested in France. For an executive of a big social media company to face a criminal enquiry is highly unusual. Mike Isaac, Tech Correspondent of The New York Times and Steve Rosenberg, Russia Editor for BBC News discuss the case. The Onion, the satirical news website, is relaunching a print edition. Its editor, Chad Nackers, explains the appeal of a traditional newspaper. A Chinese produced video game, Black Myth: Wukong, has become one of the most successful launches ever. Keza McDonald, Games Editor at The Guardian and Frankie Ward, e-sports host and broadcaster discuss this - and other gaming news. Presenter: Ros Atkins Producer: Simon Richardson Assistant Producer: Lucy Wai

This week, Robert Chernin and Ericka Redic are joined by Steve Rosenberg, Principal of the GSD Group, author of MAKE BOLD THINGS HAPPEN: Inspirational Stories from Sports, Business, and Life, and pro-Israel advocate. In this episode, Robert, Ericka, and Steve discuss Israel Appreciation Day 2024, his work with various NGOs in Israel and the United […]

After the detention in France of Pavel Durov, owner of the controversial Telegram app, we explore what the first arrest of a social media boss means for content regulation and freedom of speech. As a new parliamentary term begins, we find out how the new Labour government is managing the media. Also in the programme, there's a new Chinese computer game which is breaking records – and revealing details of how the gaming industry is evolving. Plus, satirical outlet The Onion is returning to print. We find out why.Guests: Mike Isaac, Tech Correspondent, The New York Times; Steve Rosenberg, Russia Editor, BBC News; Matt Chorley, Presenter, BBC Radio 5 Live; Eleanor Langford, Political Reporter, The i; Keza MacDonald, Games Editor, The Guardian; Frankie Ward, eSports broadcaster; Chad Nackers, Editor, The Onion Presenter: Ros Atkins Producer: Simon Richardson Assistant Producer: Lucy Wai

Kate Adie presents stories from Russia, Nigeria, the US, Ecuador and Italy.Ukraine's surprise attack on Russia's western border region of Kursk caused authorities to declare a state of emergency there. The incursion is now in its second week and is the deepest into Russian territory since Vladimir Putin launched his invasion. Steve Rosenberg has been watching the reaction in Moscow and reflects on another major news event soon after he first arrived in Russia.Nigeria has been in the throes of an economic crisis which earlier this month led to 10 days of protests across the country. More than 700 demonstrators were arrested, 22 were killed and many more were injured. The marches eventually petered out but the causes of their discontent, though, don't look likely to go away. Simi Jolaoso has been to an open-air market in Lagos.In certain US states, parents are offered school vouchers as a means of paying for their children to go to private school, should they so choose, using public funding which would otherwise be used for state-funded school places. The vouchers scheme has polarised communities across the state of Arizona, says Mark Moran in Queen Creek.In Ecuador, President Daniel Noboa has moved to clampdown on organised crime and the drug cartels since he took power, amid a surge in outbreaks of violence. Danny Wiser was in Guayaquil, which has seen the worst of the violence and learned how it's impacting key areas of daily life.The Italian city of Trieste has a complex identity, thanks to its history and its geography. It was once part of the Austro-Hungarian empire. Sara Wheeler found out more about its past on a visit this Summer.Series Producer: Serena Tarling Editor: Tom Bigwood Production Coordinators: Sophie Hill & Katie Morrison

Today, we look at the latest inflation figures and how Russian state media are covering Ukraine's continuing advance into Russia.James Cook is in for Adam, and he's joined by political correspondent Alex Forsyth and chief economic correspondent Dharshini David to discuss the rise in the rate of UK inflation. They also talk about the Scottish government's spending cuts, which include no longer providing winter fuel payments to all pensioners.And Russia editor Steve Rosenberg speaks to James from Moscow about Ukraine's advancements into Russia. You can join our Newscast online community here: https://tinyurl.com/newscastcommunityhereYou can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers.Newscast brings you daily analysis of the latest political news stories from the BBC. It was presented by James Cook. It was made by Chris Flynn with Miranda Slade, Gemma Roper and Kris Jalowiecki. The technical producer was Michael Regaard. The assistant editor is Chris Gray. The senior news editor is Sam Bonham.

Steve Rosenberg, Russia Editor for BBC News, discusses the reaction in Moscow to the ncursion by Ukranian troops, the first time in 80-years foreign troops are fighting on Russian soil.

How has the shock cross-border offensive gone down in Russia?We hear from Nikita, whose family and friends live in Kursk, about what they've been witnessing and how worried they are.BBC Russia editor, Steve Rosenberg, tells us how this is going down in the Kremlin and what President Putin might down nextAnd Olga Robinson from BBC Verify is in the studio to help us understand the picture more clearly. Today's episode is presented by Jamie Coomarasamy and Vitaly Shevchenko. The producers were Arsenii Sokolov, Cordelia Hemming, Ivana Davidovic and Hatty Nash. The technical producer was Jonny Hall. The series producer is Tim Walklate. The senior news editor is Richard Fenton-Smith. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Today, now that the election dust has settled, what challenges do the new Labour government face in their first few days? One issue that is already demanding Labour's attention is the Tata Steelworks in Port Talbot in South Wales, with thousands of jobs currently at risk. And, the Conservatives are in search of a new leader. Potential contenders, Victoria Atkins and Robert Jenrick spoke to Laura this morning. Are they putting their names in the hat? And who is being touted as a potential caretaker leader?Plus, Henry channels his inner Steve Rosenberg by sharing his ability on the piano! You can join our Newscast online community here: https://tinyurl.com/newscastcommunityhere Newscast brings you daily analysis of the latest political news stories from the BBC. It was presented by Adam Fleming. It was made by Jack Maclaren with Josh Jenkins. The technical producer was Riccardo McCarthy . The assistant editor is Chris Gray. The editor is Sam Bonham.

Kate Adie presents stories from Russia, The Netherlands, Taiwan, Vanuatu and Germany.The trial of US journalist, Evan Gershkovich in the city of Yekaterinburg will be conducted behind closed doors. He is just one of many journalists who went to Russia to report on the country, as Vladimir Putin's clampdown on media freedoms intensified. Steve Rosenberg was in Yekaterinburg and reflects on Russia's handling of the case.Last year, just over 9000 deaths - around 5% of the total number - occurred as a result of euthanasia in the Netherlands, where it's legal. It's very rare, but every year, there are more Dutch couples choosing to end their lives at the same time. Linda Pressly met someone whose parents made the decision to die together.In Taiwan, civil liberties are strongly supported, and it is now one of the world's most progressive countries regarding gay rights. On a recent visit to the capital Taipei, Lucy Ash meets some who fear that should China invade in the future, hard-won rights could be taken away.In the South Pacific, Vanuatu is grappling with what happens when a significant proportion of its workforce is lured away by higher paid jobs in hospitality, agriculture and elderly care to the likes of New Zealand and Australia. In Port Vila, Rebecca Root speaks to locals about what that means for a country struggling to build up its own economy.And finally, the UEFA Euro 2024 football championship is taking place at a time when Europe is seeing many political rifts. On a tour of some of the host cities in Germany, James Helm reflects on how football tournaments still have the power to unite rather than divide.Series Producer: Serena Tarling Editor: Richard Vadon and Tom Bigwood Production Coordinator: Katie Morrison

On Wednesday, Evan Gershkovich, the Wall Street Journal reporter arrested in Russia last year goes on trial. Russian officials have accused the Wall Street Journal reporter of collecting "secret information" from a Russian tank factory for the CIA. An allegation he denies. The BBC's Steve Rosenberg is in the city of Yekaterinburg where the trial is taking place. And we also hear from Evan's friend Polina Ivanova, and his boss at the Wall Street Journal, Deborah Ball.Today's episode is presented by Vitaly Shevchenko. Produced by Clare Williamson with Josh Jenkins, Bella Saltiel and Sanjana Idnani. The technical producer was Rohan Madison. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

In this episode of the Blue Gems podcast, the focus is on building successful businesses with Steve Rosenberg. Steve shares three crucial aspects for business success, the importance of leadership, creating systems over people-focused operations, and maintaining a forward-thinking mindset to ensure business growth and sustainability. Top takeaways from this episode include: 1) Focus on the Essentials of Business: Emphasize monetization (sales and marketing), systemization (creating efficient systems), and duplication (training and scaling with a capable team). 2) Mindset and Leadership: Successful businesses start with the right mindset and strong leadership. Leaders must inspire and create a vision that their team can rally behind while also holding themselves accountable. 3) Importance of Creating Memories: Beyond financial success, building a business should provide the freedom to create meaningful memories with loved ones, as these moments are invaluable and irreplaceable. Follow Steve online: https://www.instagram.com/rozenbergsteve/ Let's connect! ► Blue Gems Instagram: https://www.instagram.com/bluegemsgroup/   ► JB's Instagram: https://www.instagram.com/jbinvested/ ► Aidan's Instagram: https://www.instagram.com/aidangroll/ ► Blue Gems STR Management: https://bluegemsmgmt.co ► STR Meetup: https://bluegemsgroup.com Timestamps: 00:00 - Intro 02:32 - Steve's Background: Upbringing and motivation. 07:26 - Lessons from property management. 08:12 - Transitioning from investor to business owner. 23:41 - Key components for business success. 36:18 - Generating consistent business growth. 48:00 - Continual growth and self-improvement. 52:30 - Navigating Business Partnerships: Clear communication and roles. 57:05 - Developing a success-oriented mindset. 59:00 - Importance of being a lifelong learner. *None of this is meant to be specific investment advice, it's for entertainment purposes only.

What are the prospects for any progress at next week's peace summit in Switzerland, especially if Russia is not there? Our Russia editor, Steve Rosenberg and international editor, Jeremy Bowen give us their thoughts and also answer questions on Russia's economy, whether Russians are worried about Western missiles and how Ukrainian journalists are covering the war.Today's episode is presented by Victoria Derbyshire. Today's episode was produced by Clare Williamson with Paige Neal-Holder and Bella Saltiel . The technical producer was Gabriel O Regan. The series producer is Tim Walklate and the senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Dr. Diwakar Davar and Dr. Jason Luke discuss key abstracts from the 2024 ASCO Annual Meeting that explore triplet therapy in advanced melanoma, TIL cell therapy in immune checkpoint inhibitor–naive patients, and other novel approaches that could shape the future of immunotherapy in melanoma and beyond.  TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Diwakar Davar. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I'm delighted to have my friend and colleague, Dr. Jason Luke, on the podcast today to discuss key abstracts in melanoma and immunotherapy that will be featured and highlighted at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the director of the Cancer Immunotherapeutic Center, as well as the associate director for clinical research at the University of Pittsburgh's Hillman Cancer Center.  You will find our full disclosures in the transcript of this episode.  Jason, as always, it's a pleasure to have you on this podcast to hear your key insights on trials in the immunotherapy space and melanoma development paradigm, and to have you back on this podcast to highlight some of this work.  Dr. Jason Luke: Thanks so much for the opportunity to participate. I always enjoy this heading into ASCO.  Dr. Diwakar Davar: We're going to go ahead and talk about three abstracts in the melanoma space, and we will be starting with Abstract 9504. Abstract 9504 essentially is the RELATIVITY-048 study. It describes the efficacy and safety of the triplet nivolumab, relatlimab, and ipilimumab regimen in advanced PD-1 naive melanoma. So in this abstract highlighted by Dr. Ascierto and colleagues, they report on the results of this phase 2 trial in this setting. By way of background, PD-1 inhibitors and immune checkpoint inhibitors starting in PD-1 and CTLA-4, as well as PD-1 and LAG-3, are all FDA-approved on the basis of several pivotal phase 3 trials, including KEYNOTE-006, CheckMate-066, CheckMate-067, and most recently, RELATIVITY-047. Jason, can you briefly summarize for this audience what we know about each of these drugs, at least the two combinations that we have at this time?  Dr. Jason Luke: For sure. And of course, these anti PD-1 agents, became a backbone in oncology and in melanoma dating back to more than 10 years ago now, that response rates in the treatment-naive setting to anti PD-1 with either pembrolizumab or nivolumab are roughly in the range of mid-30s to high-40s. And we've seen clinical trials adding on second agents. You alluded to them with the seminal study being CheckMate-067, where we combined a PD-1 antibody and CTLA-4 antibody or nivo + ipi. And there the response rate was increased to approximately 56%. And more recently, we have data combining PD-1 inhibitors with anti-LAG-3. So that's nivolumab and relatlimab. Now, in that trial, RELATIVITY-047, the overall response rate was described as 43%. And so that sounds, on a first pass, like a lower number, of course, than what we heard for nivolumab and ipilimumab. We have to be cautious, however, that the cross-trial comparison between those studies is somewhat fraught due to different patient populations and different study design. So I think most of us think that the response rate or the long-term outcomes between PD-1, CTLA-4, and PD-1 LAG-3 are probably roughly similar, albeit that, of course, we have much better or much longer follow up for the nivo + ipi combo.  The one other caveat to this, of course then, is that the side effect profile of these two combinations is distinct, where the incidence of high-grade immune-related adverse events is going to be roughly half with nivolumab and relatlimab, a combination of what you would see with the nivolumab and ipilimumab. So that has caused a lot of us to try to think about where we would use these different combinations. But we do see that all of these treatments can land a durable long-term response in the subset of patients that do have an initial treatment benefit. The landmark, I think, for the field has been the 7-and-a-half-year median overall survival that we've seen with PD-1 plus CTLA-4, nivo + ipi; of course, we don't have such long-term follow up for PD-1 and LAG-3. But I think that's the setting for thinking about the rationale for combining a triplet regimen of PD-1, CTLA-4, and LAG-3. Dr. Diwakar Davar: So, Jason, in your mind, given the difference in the disparity and durability of the responses for the 067 regimen of nivo-ipi, and the RELATIVITY-047 regiment of nivo-rela, what is the standard of care in the U.S., and how does it change in the rest of the world, knowing that nivo-rela is not necessarily approved in all jurisdictions? Dr. Jason Luke: So this is a major complication in our field, is that there is perhaps not complete agreement across the world in terms of what the frontline standard of care should be. I think most United States investigators, or those of us that really treat melanoma most of the time, would suggest that a combination regimen, given the enhanced response rate and longer-term outcomes, should be the consideration for the majority of patients. In fact, in my practice, it's hard to think of who I would treat with a monotherapy PD-1 approach in the PD-1 naive setting. So either nivo + ipi or nivo + rela. As you alluded to however, in other regulatory settings throughout the world, combinations might not actually even be approved at this point. So PD-1 monotherapy would be the backbone of that setting. It does set up some complications when you think about a comparator arm; say you were going to look at various combinations, probably PD-1 monotherapy would be the worldwide comparator. You have to understand though, in the United States, I think that that's a less attractive option. Dr. Diwakar Davar: So in RELATIVITY-047, Dr. Ascierto and his colleagues are looking at generating a triplet. And in this case, they looked at this in the context of frontline metastatic melanoma, 46 patients. Very interestingly, the dose of ipilimumab studied here was 1 mg/kg through 8 weeks, not the 3 mg/kg every three weeks times four doses using 067, or even the low dose ipilimumab regimen that you studied in the second line setting, which was 1 mg/kg every 3 weeks for 4 doses. So let's talk about the results and specifically the implications of potentially studying lower doses of ipi. Dr. Jason Luke: I appreciate you raising that point. I think it's really important as we think about this dataset because this triplet regimen is not by any means the only version of a triplet that could be developed using these agents. So just to give the high-level numbers from the abstract, we see from these data that the overall response rate is described as 59% and 78%, a disease control rate with patients having an unreached link. So duration of response of unreached, and then the progression-free survival at about 5 months. So those are really interesting data. But as was alluded to, it's not totally clear to me that that's the best that we could do with this regimen.   Now, you alluded to this low-dose ipilimumab schedule at 1 mg/kg every 8 weeks, and it's really important to note that we have no benchmark for that regimen in melanoma oncology. And in fact, the one study that used that regimen, which was the adjuvant study of nivolumab and ipilimumab, known as CheckMate915, is in fact the only immune checkpoint inhibitor study in melanoma oncology that was actually negative. That study noted no benefit to adding ipilimumab at 1 mg/kg every 8 weeks on top of nivolumab, again, the adjuvant setting. So it's a little bit curious to then understand what it means in this study to have that amount of ipilimumab added to the rela-nivo backbone. And that manifests in a few different ways. We see the response rate here at 59%. Again, if you compare that just against the standard nivo + ipi dosing schedule, it's about the same. So is that really an advantage to having the triplet as compared to just doing standard nivo + ipi?   We do see that it manifests in a slightly lower rate of grade 3/4 immune-related adverse events, at 39%. That's a little bit lower than what we'd expect for standard nivo + ipi. But again, I think that that emphasizes to me the possibility that some efficacy was left on the table by using this very low dose ipilimumab regimen. I think that's really a concern. It's not clear to me that these triplet data really differentiate from what we'd expect with the already approved regimen of nivo + ipi. Therefore, it makes it difficult to think about how would we really want to move this regimen forward, or should there be more work done about dose and schedule to optimize how we might want to do this?  Dr. Diwakar Davar: As far as triplet therapy in the context of frontline metastatic melanoma, meaning triplet immune therapy, because there are at least several targeted therapy triplets that are FDA-approved, [but] not necessarily widely utilized. How would you summarize the future for triplet therapy? Do you think it's potentially attractive? Do you think it's very attractive with some caveats? Dr. Jason Luke: Well, I think it's attractive, and we have 3 independently active agents. And so I do think it's a priority for the field to try to figure out how we could optimize the therapy. We've had such a revolution in melanoma oncology, talking about 7.5-year median survival from CheckMate-067, but that still implies that 7.5 years, half the patients have passed away. There's more to do here. And so I do think it should be a priority to sort this out. I guess I would be cautious, though, about advancing this regimen directly to a phase 3 trial because it doesn't seem clear to me that this is optimized in terms of what the outcome could be. If we're willing to tolerate higher rates of toxicity from other dose schedules of nivo-ipi alone, then I think we should do a little bit more here to potentially explore the space that might be possible to increase that overall response rate a little more without getting into a completely exaggerated toxicity profile that would be unacceptable. So, I do think it's exciting, but there's possibly more to do before really think about going big time with this. Dr. Diwakar Davar: Great. So now we'll switch gears and move from frontline metastatic melanoma to the second line and beyond looking at a new agent and contextualizing the effects of that actually in the frontline settings. So Abstract 9505 describes the efficacy and safety of lifileucel, which is essentially autologous tumor-infiltrating lymphocyte cell therapies, also known as TIL, in combination with pembrolizumab in patients with ICI naive, so not necessarily pretreated, but ICI naive metastatic or unresectable melanoma. This is data from the IOV-COM-202 Cohort 1A oral abstract presented by Dr. Thomas and colleagues. In this abstract, Dr. Thomas and colleagues are presenting data from the 1A cohort, which is the phase 2 portion of the frontline trial that is evaluating autologous TIL with pembro in checkpoint inhibited naive metastatic melanoma.  By way of background, TIL is FDA approved on the basis of several cohorts from a phase 2 trial. The data has been presented multiple times now by Drs. Sarli, Chesney, and multiple colleagues of ours. And essentially autologous TIL, which is generated from a surgical procedure in which a patient undergoes a surgery to extract a tumor from which T cells are then grown after ex vivo expansion and rapid expansion protocol. The entire procedure was essentially pioneered by several colleagues at the NCI, primarily Dr. Steve Rosenberg, and this approach produces objective response rates of approximately 31% to 36%. And the most recent publication demonstrated that at median follow up of approximately 2 years, the median duration of response was not reached. The median OS was about 14 months and PFS was about 4 months or so. So, can you contextualize the results of the abstract in the frontline setting? And then we'll talk a little bit about where we think this is going to go. Dr. Jason Luke: So I think this is a timely study given the recent approval. And in the abstract presented here, we see an early data cut from the PD-1 naive study, as you alluded to. So here we had 22 patients and distributed across various states of advanced melanoma. Ten out of the 22 had M1C, but there also were smatterings of earlier M1A and M1B at 18.2% and 9.1%. So this is important, as we think who the treatment population is that's going to be optimized with a TIL procedure. The median sum of diameters, meaning how much tumor burden the patients have, was about 5.5cm, and I'll note that that's a relatively modest amount of tumor burden, albeit not that unusual for an early-stage trial. So of the patients that participated, 8 had BRAF mutations so that's 36%. That's not that high, but it's reasonable. And I think the important overlying number, the response rate so far in the study, with about 17 months of follow up, was 63.6%, and that includes 22% or 23% having complete response. So those are interesting data.  And another point that was made in the abstract, which we've all seen, is that responses to TIL, all of immunotherapy but especially TIL, do seem to mature over time, meaning they deepen over time. So it's possible the response rate could go up some extent as we watch this study advance. So I think these are exciting data on some level. Also, a 63.6% response rate sounds pretty impressive, but we do have to put that in the context of a double checkpoint blockade, which we just got done discussing, gives you almost a 60% response rate, 59% response rate. So then the question really is: Is it worth the amount of effort that we could go into generating a TIL product in a treatment naive patient, and put them through the lymphodepletion that is associated with TIL and the high dose interleukin 2 treatment that accompanies the reinfusion of the TIL, if you're going to get a response rate that's roughly the same as what you would get if you gave them off the shelf nivo plus ipilimumab?  At this point it's a little bit hard to know the answer to that question. I think it could be possible that the answer is yes, because we don't know exactly which populations or patients are most likely to benefit from each of these therapies. And if it could be teased out who's not going to benefit to nivo + ipi from the get-go, then of course, we would want to offer them a therapy that has that frontline potential, durable, long-term response. But I have to say, on a one-to-one with TIL therapy, you get a lot of toxicity initially with the treatment; with nivo + ipi on the back end, you get a fair amount of toxicity with the treatment. How are we going to judge those two things? And I think we probably need a larger dataset to really have a good handle on that.  So these are interesting early data, but it's not totally clear to me that even if this holds up all the way through the trial, and we're going to talk about the design of the registration trial here in a second, a 60% response rate on its own without further biomarker stratification is a little bit hard for me to see in clinical practice why we would want to do that, given we can already just go off the shelf and give checkpoint inhibitors. Dr. Diwakar Davar: So that brings us to TILVANCE-301. So TILVANCE is a phase 3 trial. It's a registration intent trial by our Iovance colleagues evaluating the pembro-TIL regimen versus pembrolizumab alone. So in this phase 3 trial, approximately 670 patients will be randomized to either arm A, which is lifileucel + pembro. And in this arm A, patients are going to be getting lifileucel with the tumor resection, non-myeloablative lymphoid depletion, the lifileucel and abbreviated course of high-dose IL-2, and thereafter, continued pembro for the study mandated duration versus arm B, where patients will be getting just pembrolizumab monotherapy per label. Arm B patients, per the design, may cross over to receive TIL monotherapy at the time of central-blinded, radiology-confirmed disease progression.   The study design otherwise is fairly routine and, per most of our registration trials these days, patients have actually been permitted to receive neoadjuvant and adjuvant therapy, including checkpoint inhibitors, as long as the receipt of the therapy was more than 6 months prior to the inclusion of the patient in that registration trial. The dual primary efficacy endpoints as stated are BICR-assessed objective response rate as well as PFS, and the key secondary endpoint is overall survival.   So Jason, what are your thoughts on the study design and potentially the regulatory implications, particularly given, one, the control arm of pembro monotherapy, and two, the role of TIL crossover to receive TIL monotherapy at the time of BICR mandated progression for arm B? Dr. Jason Luke: So this goes to a few points that we've touched on already in the discussion here. When we think about the primary endpoints for this study, with one of them being overall response rate, one has to assume that that's a given that they would get that. I feel like that's a low bar. And we go back to that cross-trial comparison. If their results end up being that the response rates are about 60%, I don't know that that differentiates necessarily from what's already available in the field with combination immune checkpoint blockade. For the purposes of the study that would mean it's a positive study, so I think that would probably be good. But again, the comparator to pembrolizumab monotherapy, I think some of us would argue, isn't really consistent with what we would do with a patient in our clinic. So it's not that it's bad per se, but I think there's going to be a whole lot of cross-trial comparison. So if the study is positive, that would be good for getting the drug available. It's still a bit hard though, based on the preliminary data that I've seen, to imagine how this would have uptake in terms of utilization as a frontline therapy.  You alluded to the crossover, and I think there, the assumption is that patients who get TIL therapy as a second line perhaps would have an attenuated benefit. But I'm not sure that's really true. It certainly looks from the data that we have, like the patients who benefit most from TIL are going to be those who didn't respond to anti PD-1 in the front line. So I'm not sure how much difference there's going to be between first- and second-line TIL therapy, but those data will kind of wait to be seen. So I think it's an important study. Of course, the accelerated approval of TIL as a later line therapy is dependent on this trial being positive. So there is some risk that if this trial ended up not being positive, that that could have regulatory implications on the utility or availability of TILs, a subsequent line therapy. But all of these, I guess we'll have to wait to see the results. We do hope for a positive trial here, although I think it'll be nuanced to sort of interpret those data given that pembrolizumab monotherapy control arm.  Dr. Diwakar Davar: Fantastic. So we've learned a lot about TIL, both its use in the second-line setting and this very exciting but potentially risky frontline trial that is ongoing at some centers in the United States and certainly a lot of ex-U.S. enrollment.   So we'll now pivot to a related product which actually belongs to a much larger class of agents that are antigen specific T-cell therapies in a variety of different formats. And that is Abstract 9507, which is the “Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).” Now, in this abstract, Dr. Omid Hamid and colleagues reported the results of this phase 1 trial. As a disclosure, I'm an investigator and the last author on this manuscript. Jason, it would be important for our audience, for us to maybe firstly, outline the PRAME as a target, and then the ImmTAC as a platform prior to discussing these results. So let's start with the target PRAME, which I think is a target that you know well. So why don't you start with the target and we'll talk a little bit about that and then the platform? Dr. Jason Luke: Yeah, so I think for the audience, being aware of PRAME, or the Preferentially Expressed Antigen in Melanoma, is going to be quite important moving into the future. So PRAME as a therapeutic target is a cancer testis antigen that's overexpressed in tumor tissues. And of course the name has melanoma in it, but it's not uniquely present in melanoma. So the expression patterns of PRAME as a target are very high in melanoma. So in cutaneous disease, this is upwards of almost 100%, somewhere between 95% and 100%, in metastatic melanoma tissues. And PRAME has several different roles on a molecular level, although I don't think for our purposes here, it's so much important to be aware of them, but rather that this is a very highly expressed target, which then can make it attractive for using T cell receptor-based therapies. And so in the case we're talking about here on the ImmTAC platform, that's a CD3 PRAME×CD3 bispecific approach. But of course there are other approaches that can also be taken, such as TCR T cells that directly go after PRAME itself. Dr. Diwakar Davar: Let's now talk about the platform and how it differs from some of the other antigen targeting platforms that you have just alluded to. I think the Immtac platform is basically a fusion protein comprising engineered TCRs with a CD3 specific short chain variable fragment. And then the engineered TCR therefore binds antigens in an HLA dependent fashion. But you know quite a lot about some of these alternative platforms, and I think it'll be important to contextualize for the audience the difference between ImmTAC, which is a prototype drug that is already approved in the context of tebentafusp. But how does this differ from some of the other more nuanced platforms, such as the Immatics TCR or TCR platform and TScan TCRT nanoplasmonic platform.  Dr. Jason Luke: Right. So the ImmTAC platform as alluded to is already approved on the market with tebentafusp, which is the gp100-CD3 bispecific molecule. And the advantage of that approach is infusion off the shelf of a drug. The downside of it is that it is a weekly dosing strategy as it stands now. And there are some complicated disease kinetics associated with treatment response, which we'll come back to in the context of the PRAME bispecific. Those are, in contrast with T-cell receptor-transduced T cells, as an alternative strategy, which is a form of adopted cell transfer. So we just got done talking about TIL therapy, which of course, is trying to take lymphocytes out of the tumor and grow them up and then give them back. Here with TCR-transduced T cells, we're talking about taking leukopak from the blood and then using different transfection approaches to try to insert into the lymphocytes of the patient a T cell receptor that recognizes to a certain cancer antigen, in this case, PRAME.  So you alluded to a couple of different companies that have different platforms to do this. Immatics has a molecule called IMA 203, for which there have been data disclosed in the past year, again showing some very interesting responses in patients who have highly refractory melanoma. That process, though, again, does require lymphodepletion before you reinfuse the cells. Again, in contrast, the ImmTAC, which is an off the shelf revenue administer, there you have to make the product and then bring the patient back, lymphodeplete, and give the cells back. Immatics platform uses a viral transfection vector. The T scan approach that you alluded to before uses an approach of a mixed system on multiple HLA backgrounds to try to get past HLA-A*02:01 only, and in this case, uses a plasmid-based transfection syndrome that perhaps can be more broadly utilized given the lack of a lentiviral vector.   So this is a complicated area of technology that starts to get into immune engineering, and I think for the purposes of this discussion, we don't want to belabor it. But both of these technologies, talking about the CD3 bispecific with the off the shelf aspect of it and the adoptive cell transfer, each of these using a T cell receptor-based therapy to try to go after PRAME, I think have very high upsides, and I think we'll initially see it in melanoma over the next year or so. But this is likely to be relevant to multiple tumor types beyond melanoma.  Dr. Diwakar Davar: So let's discuss the results of this phase 1 trial. IMC-F106C, like all other ImmTAC, is administered intravenously and does require step-up dosing. You alluded to the fact that the tebentafusp was approved, and it's one of those drugs that is fortunately otherwise administered weekly, which can be difficult for the patient and requires at least the patient spend the first 3 doses overnight under some kind of monitoring, whether it's in the hospital or extended outpatient monitoring, for at least 23 hours. The efficacy of this agent and this platform appears to be surprising in that you tend to see a relatively low RECIST response rate. We'll have you comment a little bit on why that is the case and what may be the role of ctDNA, as opposed to conventional RECIST in assessing response.   At least in this trial, they mandated pre-testing, but did not require it for study enrollment. And pre-positivity was defined using immunohistochemistry with a relatively low H-score of 1%. And the molecular response definition was a 0.5 log or a 68% ctDNA reduction just prior to the first imaging assessment. So how do you contextualize the results? But maybe before you talk a little bit about the results, the ctDNA aspect, that was a recent publication by Drs. Rich Carvajal, Alex Shoushtari, and I think you are also involved in that.  Dr. Jason Luke: So, I think an interesting observation around tebentafusp has been that ctDNA may be a better predictor of long-term outcomes. And how you define ctDNA response is still something that the field is grappling with, albeit that I think is going to be an important consideration as we think about these novel therapies, these ImmTACs and other CD3 engagers moving into the future. But for the purposes of the abstract here, we see that in the population of patients treated, there were 46 patients with cutaneous melanoma. The majority got monotherapy with IMC-F106C, and that's the PRAME bispecific. So 40 patients that got monotherapy and six who got a combination with checkpoint inhibitor. All these patients had prior treatment with immunotherapy, and most of them had PD-1 and CTLA-4 antibody with a small spanner that also had BRAF inhibitors.  In terms of that PRAME testing that you alluded to, based on the immunohistochemistry H-score greater than 1%, 35 out of 40 patients were positive, so they defined 5 as negative. And we could come back if we have time, but there are other ways to do PRAME testing as well that I think may become unique for different agents, maybe an important biomarker. In the data, 31 out of the 46 patients were RECIST evaluable. The outcomes of those patients were to note that the response rate was 13%, which was four partial responses. But 35% of patients had tumor regression with a disease control rate at 65%. It was clear that there was an enrichment by PRAME positivity for both progression free and overall survival. So those patients who had obvious positivity essentially had a doubling of the PFS and more than the doubling of the OS, 2.1 to 4.1 months for TFS and landmark OS, 40% to 94%. So I think these are quite intriguing data.  It does suggest that for the vast majority of patients, we do see some induction of the antitumor effect, albeit that RECIST might undercall the effect. And so this may become another area where the ctDNA monitoring might be able to help us to understand who is likely to have really long-term benefit from this therapy. And given the number of emerging treatments that we have for melanoma, we might be able to really focus in on that group of patients in terms of optimizing how we would use this drug moving into the future. Dr. Diwakar Davar: So you talked about a response rate, and at first glance, this response rate is a little underwhelming. We're talking about 4 out of 31 RECIST evaluable patients, 13%. So it's in the double digits, but barely. So how enthusiastic are you about the results? How does it contrast with at least the publicly known data from other brain targeting approaches, such as the IMA203 agent, understanding that while they may be all targeting somewhat the same target, they are actually extraordinarily different platforms. One's off the shelf, one's highly customized. How do you contextualize the results? How would it contrast with other cellular approaches?  Dr. Jason Luke: I think it's important, again, to emphasize the point you made, which is that they're very different kinds of treatments. So even though they both target PRAME, they're going to be differently useful, and they could be quite useful for different groups of patients. And so here we see that there is a subfraction of patients who are deriving long-term benefit. And we commonly have an argument in our field about, is overall response rate really a useful monitor that describes a patient-centric outcome? While, of course, patients like to know their tumors are shrinking, what they want the most is for the tumors not to get worse and for them not to pass away from cancer. So I think I'm enthusiastic about these results, but emphasizing the point that we need to better understand who is going to benefit the most from this CD3 bispecific PRAME approach and how we're going to be able to harness that into long term benefit for patients because there's no doubt that an off the shelf therapy has a high degree of value relative to adoptive cell transfer, which sort of requires a big wind up.   So when you say, what does it contrast with? Well, the data for IMA203 has shown more than a 50% response rate in patients with more than 5 lines of therapy for metastatic disease. That really looks quite exciting. And several of those patients are now out for quite an extended period, meaning 2 years or more given only a single dose of IMA203. But again, the caveat being, you have to make the cell product for the patient, and that takes time. You lymphodeplete the patient, not all patients can tolerate that in the refractory disease setting, and then they have to be able to tolerate the reinfusion of the cells. And so this drug, IMC-F106C, looks very promising. Moving into the earlier phase trial that we'll talk about, I think the TCR T cell program has a lot of upsides for patients, especially with refractory disease. And so I think these two different approaches are really on parallel tracks. They both target PRAME, but I don't think they necessarily need to be compared one to one, as if they're going to go head-to-head with each other. Dr. Diwakar Davar: So now we'll talk a little bit about the frontline setting, because on the basis of some of these results, Immunocore is now exploring IMC-F106C frontline melanoma. This trial is actually being presented as a trial in progress at this meeting by Georgina Long and colleagues. Some of us are co-authors in that abstract. And in this study, HLA-A*02:01 positive patients with advanced unresectable melanoma will be randomized one to one to the combination of IMC-F106C, which actually, I think after this meeting will be known as bre-ni in combination with nivolumab versus nivolumab regimens, which will either be nivo or nivo-rela, investigators choice and likely dependent on region. So what do you think of the challenge of this trial? We talked about some of the challenges of the TILVANCE trial earlier. But what is going to be the challenge of this trial and in this setting, particularly given the response rates that we've seen so far? Dr. Jason Luke: Yeah, so, similar to comments we had before, thinking about what the optimal control arm is for a study like this is difficult, and so that'll be important as we think about interpreting the results. One has to assume for the purpose of this conversation that it is a positive trial, and that adding the PRAME bispecific theory does lead to an improvement in progression free survival relative to those in checkpoint alone approaches. And I think the magnitude of that difference is going to be of some relevance. And then I think importantly, also figure out who needs this treatment and who's going to benefit long term are going to be really important considerations.  We alluded to how this drug requires an intensive dosing period at the get go, and so telling patients that they need to come in weekly or bi-weekly initially for some number of weeks before they switch to a longer-term intermittent regimen, that comes with real world considerations for patients, their families, their finances, etc. So the benefit has to be clearly obvious that makes it worthwhile doing that, again, because a default could be giving drugs that we've had for 10 years with the nivolumab and ipilimumab. So there's going to be a lot of cross-trial comparison that is going to necessarily have to take place here to think about what these results really mean in the context of other available therapies.  I think the study is reasonable to do. I think this is a very active agent. There's no doubt there's a subset of patients who seem to benefit a lot from it. And I would just emphasize the point that that's probably going to be the most important thing to really drill down on is under the assumption there's a positive trial, we need to know who those people are so we could optimize giving this kind of a treatment to them. Dr. Diwakar Davar: I guess one important point to underscore what Jason said about potential predictive biomarkers, I think as part of the presentation, Dr. Hamid and colleagues will be talking about a candidate predictive biomarker of this agent, which is potentially class specific and not necessarily agent specific of a T cell signature that potentially could define patients who are more likely to benefit from this agent.  So, Jason, as always, thank you for sharing your expertise and insights with the team today. We certainly look forward to catching up again for our wrap up episode after the annual meeting where we'll talk about some of the data that we could not talk about, particularly the late breaking abstracts and other key advances that will shape the future of, certainly the field of immunotherapy and melanoma, potentially the field of cancer immunotherapy at large. Dr. Jason Luke: Oh, thanks very much for the opportunity. Dr. Diwakar Davar: And thank you to our listeners today. You'll find the links to the abstracts discussed today in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. So thank you, and we'll see you soon.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio      

Vladimir Putin has been sworn in as Russia's president for a new six-year term, just days before Russia's annual Victory Day military parade on 9 May.But why does this annual event, marking victory over Nazi Germany in 1945, matter so much to Russia now?We speak to Alexander Goncharov a former Russian military officer, who's now head of the World War Two veterans organisation in Moscow.And we discuss Victory Day's symbolism with Russia editor Steve Rosenberg and Patricia Lewis from Chatham House.Today's episode is presented by Jamie Coomarasamy and Vitaly Shevchenko. The producers were Charlie Henry and Arsenii Sokolov. The technical producer was Mike Regaard. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

We answer your questions on the US aid package for Ukraine: when will it be felt on the frontline and will it have an impact on the war?To help do this Victoria and Vitaly are joined by the former head of the US Army in Europe, General Ben Hodges, who also gives his assessment on whether Ukraine can win.And, we hear from Steve Rosenberg in Moscow who shares some news about his friend Valentina, who used to work in a newspaper kiosk.Today's episode is presented by Victoria Derbyshire and Vitaly Shevchenko. The producers were Arsenii Sokolov, Cordelia Hemming, Elliot Ryder and Miriam Quayyum. The technical producer was Mike Regaard. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Kate Adie introduces stories from Russia, Germany, Timor Leste and OmanAt a recent gathering in a gilded hall in the Kremlin, Vladimir Putin thanked VIP supporters for his re-election. As he commenced his fifth term in office, he has reminded his voters that the annexation of Crimea is just the beginning of Moscow's ambitions. Steve Rosenberg reflects on how this latest election has emboldened the President but there are voices of opposition willing to take a stand in spite of the consequences.When German Chancellor Olaf Scholz pledged the country was seeing a paradigm shift, or Zeitenwende, in supporting Ukraine in the war against Russia, he did not foresee how this would divide public opinion over Germany's potential involvement in a military campaign. Damien McGuinness reports on the ongoing political rifts in Berlin.Timor Leste has had a troubled history and faces multiple economic and social challenges including malnutrition and rural poverty. But marine scientists are discovering that Timor Leste lies on a vast migration route for a wide range of ocean wildlife, which some hope could fuel a fledgling tourism industry, reports Michelle Jana Chan.And we're in Oman, where a journey to the medieval capital of Nizwa leads to a conversation about the changes for women in the country, with a female driving instructor. Women have been legally allowed to drive in the country for more than 2 decades, unlike its neighbour Saudi Arabia, and a rise in the number of women in the workplace means more women are getting behind the wheel, says Sara Wheeler.Series Producer: Serena Tarling Editor: Richard Fenton-Smith Production Coordinator: Katie Morrison

President Putin has claimed a landslide victory in an election that featured no genuine competition. The last day of voting was marked by silent protests at polling stations. But how does his expected victory matter? And what might securing a fifth term mean for the war in Ukraine? Lyse and Vitaly are joined by the BBC's Russia editor Steve Rosenberg.Today's episode is presented by Lyse Doucet and Vitaly Shevchenko. The producer was Arsenii Sokolov. The technical producer was Rohan Madison. The series producer is Tim Walklate. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Kate Adie introduces dispatches from Ukraine, Russia, the USA and Georgia.Sarah Rainsford was in Ukraine when Vladimir Putin first launched his full-scale invasion two years ago, reporting on the defiance and rush to defend the country. On a recent trip back to the border city of Kharkiv, she found a much more sombre mood.Steve Rosenberg reflects on how the death of Russian opposition leader Alexei Navalny, along with two years of war with Ukraine, has affected the outlook of many ordinary Russians. Many wish for change, but are unclear on how that can be achieved.Over recent months, the stalled passage of a $60bn military aid package through the US Congress has heightened concerns that Washington's support for Ukraine is on the wane. Anthony Zurcher reflects on how the current US position has changed since his trip to Kyiv in the weeks before the Russian invasion began.Georgia has become a prime destination for Russians fleeing the war with Ukraine, especially those escaping conscription. The sudden arrival of tens of thousands of Russians has proved overwhelming at times, and given Georgia's own past conflict with Russia, not everyone is happy to see them, reports Vitaliy Shevchenko.Since Russia's invasion, more than 6 million Ukrainians have sought refuge overseas – but many people have stayed put, often by choice, determined to carry on living their lives as they have always done. Caroline Eden meets some market traders in Ukraine's southern port of Odessa, who are trying to ensure it's business as usual.Series Producer: Serena Tarling Production coordinator: Katie Morrison Editor: Richard Fenton-Smith

Saturday marks exactly two years of this conflict. On today's special episode, recorded in collaboration with the Global News Podcast, BBC experts from across the world answer YOUR questions on the war.Today's episode is presented by Oliver Conway and Vitaly Shevchenko, with the BBC's chief international correspondent, Lyse Doucet, in Kyiv, Russia editor Steve Rosenberg in Moscow and BBC Verify's Olga Robinson. It was made in collaboration with the Global News Podcast team. The producers were Keiligh Baker, Cordelia Hemming and Ivana Davidovic. The technical producer was Mike Regaard. The series producer is Lucy Boast. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord

Two years on from the start of the full-scale Russian invasion of Ukraine, the BBC's Russia editor, Steve Rosenberg, has been asking Russians what they think of the war. Also in the programme: Albania gives the green light to a controversial migrant processing centre - on behalf of Italy; and a court ruling in the US state of Alabama is enough to shut down some IVF treatment - as physicians run scared of being sued.(Photo: A mural of fallen Russian soldiers in Solnechnogorsk. Credit: BBC)

What's it like living in the Russian city under attack?We hear from a man in Belgorod, the Russian border city that Ukraine is targeting with missiles.Twenty-five people were killed and more than 100 others hurt there on 30 December, in what was one of the deadliest attacks on Russia since the full scale invasion. Missiles continue to be fired.Russia editor Steve Rosenberg is on to tell us how Russians are reacting, and what it means for the future of the war.Today's episode is presented by Victoria Derbyshire and Vitaly Shevchenko. It was made by Chris Flynn. The producers were Cordelia Hemming, Ivana Davidovic, Ben Tavener and Clare Williamson. The technical producers were Jack Graysmark and Philip Bull. The series producer is Lucy Boast. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480.You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord.

As the war in Ukraine approaches its second anniversary, what does 2024 hold for the conflict?BBC correspondents from across the world join us for a one-off special, looking at how elections in the UK, US and Russia will affect funding and the frontline.Europe editor Katya Adler, Russia editor Steve Rosenberg, Ukraine correspondent James Waterhouse and US State Department correspondent Barbara Plett Usher join us to answer your questions.Today's episode is presented by Lucy Hockings. The producers were Keiligh Baker, Clare Williamson, Arsenii Sokolov and Ivana Davidovic. The technical producer was Mike Regaard. The series producer is Lucy Boast. The senior news editor is Sam Bonham. Email Ukrainecast@bbc.co.uk with your questions and comments. You can also send us a message or voice note via WhatsApp, Signal or Telegram to +44 330 1239480You can join the Ukrainecast discussion on Newscast's Discord server here: tinyurl.com/ukrainecastdiscord